Drugs / [99mTc]Tc-BQ0413
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06101927 | Oct 2023 → May 2024 | prostate cancer | Tomsk National Research Medical Center of the Russian Academy of Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [99mTc]Tc-BQ0413 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06101927 ↗ |
| Known as | technetium-99m labeled BQ0413 | “The overall goal is to study the effectiveness of SPECT imaging prostate cancer patients Using technetium-99m labeled BQ0413.” NCT06101927 ↗ |
| Route | Intravenous | “One single intravenous injection of \[99mTc\]Tc-BQ0413” NCT06101927 ↗ |